HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (5- (cyclopropylcarbamoyl)- 2- methylphenylamino)- 5- methyl- N- propylpyrrolo(1,2- f)(1,2,4)triazine- 6- carboxamide

structure in first source

Also Known As:

BMS 582949; BMS-582949; BMS582949; PS 540446; PS-540446; PS540446

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide: 2
  - Triazines: 306
    - 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide: 2

Experts

1.	Abdelbaky, Amr: 1 article (06/2015)
2.	Ballantyne, Christie M: 1 article (06/2015)
3.	Du, Shuyan: 1 article (06/2015)
4.	Ehlgen, Alexander: 1 article (06/2015)
5.	Emami, Hamed: 1 article (06/2015)
6.	Farkouh, Michael E: 1 article (06/2015)
7.	Farmer, Matthew: 1 article (06/2015)
8.	Fayad, Zahi A: 1 article (06/2015)
9.	Hayes, Wendy: 1 article (06/2015)
10.	Kim, Joonyoung: 1 article (06/2015)

Related Diseases

1.	Atherosclerosis 08/01/2009 - "The available evidence suggests that the compound could be BMS-582949, a compound in Phase II studies for the treatment of rheumatoid arthritis, psoriasis and atherosclerosis." 06/01/2015 - "The findings of this study demonstrates that in stable atherosclerosis, 12 weeks of treatment with BMS-582949 did not reduce arterial inflammation or hs-CRP compared to placebo, whereas intensification of statin therapy significantly decreased arterial inflammation." 06/01/2015 - "Subjects with documented atherosclerosis (n = 72) on stable low-dose statin therapy and having at least one lesion with active atherosclerotic plaque inflammation in either aorta or carotid arteries were randomized to BMS-582949 (100 mg once daily), placebo, or atorvastatin (80 mg once daily), for 12 weeks. "
2.	Atherosclerotic Plaque (Atheroma) 06/01/2015 - "This study evaluated the effect of p38 mitogen-activated protein kinase (p38MAPK) inhibitor, BMS-582949, on atherosclerotic plaque inflammation, using (18)FDG-PET imaging. " 06/01/2015 - "Subjects with documented atherosclerosis (n = 72) on stable low-dose statin therapy and having at least one lesion with active atherosclerotic plaque inflammation in either aorta or carotid arteries were randomized to BMS-582949 (100 mg once daily), placebo, or atorvastatin (80 mg once daily), for 12 weeks. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 08/01/2009 - "The available evidence suggests that the compound could be BMS-582949, a compound in Phase II studies for the treatment of rheumatoid arthritis, psoriasis and atherosclerosis."
4.	Inflammation (Inflammations) 06/01/2015 - "This study evaluated the effect of p38 mitogen-activated protein kinase (p38MAPK) inhibitor, BMS-582949, on atherosclerotic plaque inflammation, using (18)FDG-PET imaging. " 06/01/2015 - "Subjects with documented atherosclerosis (n = 72) on stable low-dose statin therapy and having at least one lesion with active atherosclerotic plaque inflammation in either aorta or carotid arteries were randomized to BMS-582949 (100 mg once daily), placebo, or atorvastatin (80 mg once daily), for 12 weeks. "
5.	Rheumatoid Arthritis 08/01/2009 - "The available evidence suggests that the compound could be BMS-582949, a compound in Phase II studies for the treatment of rheumatoid arthritis, psoriasis and atherosclerosis."

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
3.	C-Reactive Protein
4.	Atorvastatin (Lipitor)

Related Therapies and Procedures

1.	Therapeutics